Wave Life Sciences (WVE) Proxy filing summary

Executive summary

• Plans are underway to redomicile the parent company from Singapore to the United States, subject to shareholder and Singapore High Court approvals.

• A hearing for approval to convene a shareholder meeting is scheduled for April 29, 2026, with related court deadlines set for April 22 and April 24, 2026.

• The redomiciliation aims to streamline operations and potentially enhance access to U.S. capital markets.

• Forward-looking statements highlight expectations for future business and financial performance post-redomiciliation.

Voting matters and shareholder proposals

• Shareholders will vote on the proposed scheme of arrangement to approve the redomiciliation.

• Proxy materials and the definitive proxy statement will be distributed to shareholders with detailed information about the proposal.

Board of directors and corporate governance

• Directors and executive officers may be considered participants in the proxy solicitation for the redomiciliation.

• Information on directors’ and officers’ interests is available in prior proxy statements and will be updated in the definitive proxy statement.